# US 2017/0281691 A1 · Methods for constructing antibiotic resistance free vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281691 A1
- Document ID: US20170281691A1
- Status: Published application
- Kind: A1
- Application number: 15/621,411
- Filed: 2017-06-13
- Published: 2017-10-05
- Earliest claimed: 2004-08-13
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: The Trustees of the University of Pennsylvania
- Inventors: Yvonne PATERSON; Thorsten VERCH
- Web page: https://patentgrep.com/patent/US20170281691A1

## CPC

- C12N 9/1096: {transferring nitrogenous groups (2.6)}
- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 39/12: Viral antigens
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/46: Viral antigens
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 9/16: acting on ester bonds (3.1)
- C12N 9/90: Isomerases (5.)
- C12N 15/52: Genes encoding for enzymes or proenzymes
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12Y 206/01: Transaminases (2.6.1)
- C12Y 206/01021: D-Amino-acid transaminase (2.6.1.21), i.e. D-alanine aminotransferase/transaminase or D-aspartic aminotransferase/transaminase
- C12Y 501/01001: Alanine racemase (5.1.1.1)
- A61K 2039/523: {expressing foreign proteins}
- A61K 2039/585: {wherein the target is cancer}
- C12N 2710/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/20033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The present invention provides Listeria vaccine strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.

## Claims

### Claim 1

A composition comprising an antibiotic gene-free plasmid, said plasmid comprising: i) a first nucleic acid sequence encoding a polypeptide, wherein said polypeptide comprises a heterologous antigen, ii) a second nucleic acid sequence encoding a metabolic enzyme, wherein said metabolic enzyme complements a mutation or deletion in a recombinant Listeria strain's chromosome, wherein said polypeptide is a fusion protein comprising said heterologous antigen and a non-hemolytic Listeriolysin (LLO) protein or N-terminal fragment thereof.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the chromosome of said recombinant Listeria strain comprises a mutation or deletion of a gene encoding a transcription factor or wherein the chromosome lacks a gene encoding a transcription factor.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said heterologous antigen is a human papilloma virus E7 antigen (HPV-E7) or a human papilloma virus E6 antigen (HPV-E6).

### Claim 4 (depends on 1)

The composition of claim 1, wherein said first and said second nucleic acids are operably linked to a promoter/regulatory sequence.

### Claim 5 (depends on 4)

The composition of claim 4, wherein said promoter/regulatory sequence linked to said first nucleic acid is a hly promoter.

### Claim 6 (depends on 5)

The composition of claim 5, wherein said promoter/regulatory sequence linked to said second nucleic acid sequence comprises a truncated P60 promoter region.

### Claim 7 (depends on 1)

The composition of claim 1, wherein said plasmid comprises a gram positive and a gram negative origin of replication region.

### Claim 8 (depends on 7)

The composition of claim 7, wherein said gram negative origin of replication is an E. coli origin of replication.

### Claim 9 (depends on 1)

The composition of claim 1, wherein said metabolic enzyme is a D-alanine racemase enzyme or D-amino acid transferase enzyme.

### Claim 10 (depends on 1)

The composition of claim 1, wherein said plasmid does not confer antibiotic resistance upon said recombinant Listeria strain.

### Claim 11 (depends on 1)

The composition of claim 1, wherein said antibiotic gene-free plasmid further comprises a nucleic acid sequence encoding a transcription factor.

### Claim 12 (depends on 12)

The composition of claim 12, wherein said transcription factor is a prfA gene.
